Glutathione S‐transferases (GSTs) polymorphisms may impact on chronic myeloid leukemia (CML) risk or heterogeneous responses to Imatinib mesylate (IM). This evidence concerns the gene HPGDS and chronic myelogenous leukemia, BCR-ABL1 positive.